Xspray Pharma
28.00 SEK
-3.61 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-3.61 %
+9.90 %
-8.45 %
-8.45 %
-54.15 %
-2.61 %
-56.55 %
-72.05 %
-4.66 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.29B SEK
Turnover
552.25K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/4
2026
Interim report Q1'26
12/5
2026
General meeting '26
5/8
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Xspray publishes disclosure document regarding rights issue
Xspray erhåller ytterligare teckningsåtaganden; företrädesemissionen är nu täckt till 110 % och övertilldelningsemissionen utökas
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools